blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2015065

EP2015065 - METHOD OF QUANTIFYING NEUROTOXIN [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  25.04.2014
Database last updated on 27.07.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU, LU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
The Chemo-Sero-Therapeutic Research Institute
1-6-1 Okubo
Kita-ku
Kumamoto-shi
Kumamoto 860-8568 / JP
For all designated states
JAPAN as represented by DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES
23-1, Toyama 1-chome
Shinjuku-ku
Tokyo 162-8640 / JP
[2013/08]
Former [2011/41]For all designated states
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
6-1, Okubo 1-chome Kumamoto-shi
Kumamoto-ken 860-8568 / JP
For all designated states
JAPAN as represented by DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES
23-1, Toyama 1-chome
Shinjuku-ku
Tokyo 162-8640 / JP
Former [2011/38]For all designated states
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
6-1, Okubo 1-chome Kumamoto-shi
Kumamoto-ken 860-8568 / JP
For all designated states
JAPAN as represented by DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES
23-1, Toyama-cho 1-chome Shinjuku-ku
Tokyo 162-8640 / JP
Former [2009/09]For all designated states
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
6-1, Okubo 1-chome Kumamoto-shi
Kumamoto-ken 860-8568 / JP
For all designated states
JAPAN as represented by DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES
1-23-1, Toyama, Shinjuku-ku
Tokyo 162-8640 / JP
Former [2009/03]For all designated states
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
6-1, Okubo 1-chome Kumamoto-shi
Kumamoto-ken 860-8568 / JP
For all designated states
Japan as Repres. by Director Gral of National Institute of Infectious Diseases
23-1, Toyama 1-chome, Shinjuku-ku
Tokyo 162-8640 / JP
Inventor(s)01 / HARAKAWA, Tetsuhiro
JURID.FOUND. CHEMO-SERO-THERAP. RES. INST.
6-1, Okubo 1-chome
Kumamoto-shi, Kumamoto 860-8568 / JP
02 / NAKANO, Hirotoshi
JURID.FOUND. CHEMO-SERO-THERAP. RES. INST.
6-1, Okubo 1-chome
Kumamoto-shi, Kumamoto 860-8568 / JP
03 / TORII, Yasushi
JURID.FOUND. CHEMO-SERO-THERAP. RES. INST.
6-1, Okubo 1-chome
Kumamoto-shi, Kumamoto 860-8568 / JP
04 / OKUDA, Sachio
JURID.FOUND. CHEMO-SERO-THERAP. RES. INST.
6-1, Okubo 1-chome
Kumamoto-shi, Kumamoto 860-8568 / JP
05 / KAJI, Ryuji
The University of Tokushima Faculty of Medicine
18-15, Kuramoto-cho 3-chome
Tokushima-shi, Tokushima 770-8503 / JP
06 / SAKAMOTO, Takashi
Kohnodai Hosp., The Nat. Center of Neurol.&Psych.
1-7-1, Kohnodai
Ichikawa-shi, Chiba 272-8516 / JP
07 / TAKAHASHI, Motohide
National Institute of Infectious Diseases
4-7-1, Gakuen
Musashimurayama-shi, Tokyo 208-0011 / JP
08 / ISHIDA, Setsuji
19-3, Akitsu 4-chome
Narashino-shi, Chiba 275-0025 / JP
 [2011/40]
Former [2009/03]01 / HARAKAWA, Tetsuhiro
JURID.FOUND. CHEMO-SERO-THERAP. RES. INST., 6-1, Okubo 1-chome
Kumamoto-shi, Kumamoto 860-8568 / JP
02 / NAKANO, Hirotoshi
JURID.FOUND. CHEMO-SERO-THERAP. RES. INST., 6-1, Okubo 1-chome
Kumamoto-shi, Kumamoto 860-8568 / JP
03 / TORII, Yasushi
JURID.FOUND. CHEMO-SERO-THERAP. RES. INST., 6-1, Okubo 1-chome
Kumamoto-shi, Kumamoto 860-8568 / JP
04 / OKUDA, Sachio
JURID.FOUND. CHEMO-SERO-THERAP. RES. INST., 6-1, Okubo 1-chome
Kumamoto-shi, Kumamoto 860-8568 / JP
05 / KAJI, Ryuji
The University of Tokushima Faculty of Medicine, 18-15, Kuramoto-cho 3-chome
Tokushima-shi, Tokushima 770-8503 / JP
06 / SAKAMOTO, Takashi
Kohnodai Hosp., The Nat. Center of Neurol.&Psych., 1-7-1, Kohnodai
Ichikawa-shi, Chiba 272-8516 / JP
07 / TAKAHASHI, Motohide
National Institute of Infectious Diseases, 4-7-1, Gakuen
Musashimurayama-shi, Tokyo 208-0011 / JP
08 / ISHIDA, Setsuji
19-3, Akitsu 4-chome
Narashino-shi, Chiba 275-0025 / JP
Representative(s)Meier, Jürgen
Vossius & Partner
Siebertstrasse 4
81675 München / DE
[N/P]
Former [2011/40]Meier, Jürgen
Vossius & Partner Siebertstrasse 4
81675 München / DE
Former [2009/03]Meier, Jürgen
Vossius & Partner Siebertstrasse 4
81675 München / DE
Application number, filing date06745899.228.04.2006
[2009/03]
WO2006JP309040
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2007125604
Date:08.11.2007
Language:JA
[2007/45]
Type: A1 Application with search report 
No.:EP2015065
Date:14.01.2009
Language:EN
[2009/03]
Type: B1 Patent specification 
No.:EP2015065
Date:05.10.2011
Language:EN
[2011/40]
Search report(s)International search report - published on:JP08.11.2007
(Supplementary) European search report - dispatched on:EP07.04.2009
ClassificationIPC:G01N33/15, G01N33/50
[2009/03]
CPC:
G01N33/5088 (EP,US); A61P43/00 (EP); G01N33/94 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/03]
TitleGerman:VERFAHREN ZUR QUANTIFIZIERUNG VON NEUROTOXIN[2009/03]
English:METHOD OF QUANTIFYING NEUROTOXIN[2009/03]
French:PROCEDE DE QUANTIFICATION D'UNE NEUROTOXINE[2009/03]
Entry into regional phase28.10.2008Translation filed 
28.10.2008National basic fee paid 
28.10.2008Search fee paid 
28.10.2008Designation fee(s) paid 
28.10.2008Examination fee paid 
Examination procedure28.10.2008Examination requested  [2009/03]
07.07.2009Despatch of a communication from the examining division (Time limit: M04)
17.11.2009Reply to a communication from the examining division
27.11.2009Despatch of a communication from the examining division (Time limit: M06)
07.06.2010Reply to a communication from the examining division
22.11.2010Cancellation of oral proceeding that was planned for 10.12.2010
10.12.2010Date of oral proceedings (cancelled)
09.03.2011Communication of intention to grant the patent
19.07.2011Fee for grant paid
19.07.2011Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  07.07.2009
Opposition(s)Opponent(s)01  05.07.2012    ADMISSIBLE
ALLERGAN, INC.
2525 Dupont Drive
Irvine CA 92612 / US
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 [N/P]
Former [2012/33]
Opponent(s)01  05.07.2012   
ALLERGAN, INC.
2525 Dupont Drive
Irvine CA 92612 / US
Opponent's representative
HOFFMANN EITLE
Patent- und Rechtsanwälte
Arabellastraße 4
DE-81925 München / DE
22.08.2012Invitation to proprietor to file observations on the notice of opposition
27.02.2013Reply of patent proprietor to notice(s) of opposition
13.11.2013Date of oral proceedings
14.01.2014Despatch of minutes of oral proceedings
14.01.2014Despatch of communication that the patent will be revoked
24.04.2014Legal effect of revocation of patent [2014/22]
Fees paidRenewal fee
28.10.2008Renewal fee patent year 03
24.04.2009Renewal fee patent year 04
29.03.2010Renewal fee patent year 05
21.04.2011Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU28.04.2006
AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
FI05.10.2011
IT05.10.2011
LT05.10.2011
LV05.10.2011
NL05.10.2011
PL05.10.2011
RO05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
TR05.10.2011
BG05.01.2012
GR06.01.2012
ES16.01.2012
IS05.02.2012
PT06.02.2012
IE28.04.2012
LU28.04.2012
CH30.04.2012
LI30.04.2012
MC30.04.2012
[2015/34]
Former [2014/21]AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
FI05.10.2011
IT05.10.2011
LT05.10.2011
LV05.10.2011
NL05.10.2011
PL05.10.2011
RO05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
TR05.10.2011
BG05.01.2012
GR06.01.2012
ES16.01.2012
IS05.02.2012
PT06.02.2012
IE28.04.2012
CH30.04.2012
LI30.04.2012
MC30.04.2012
Former [2013/29]AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
FI05.10.2011
IT05.10.2011
LT05.10.2011
LV05.10.2011
NL05.10.2011
PL05.10.2011
RO05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
BG05.01.2012
GR06.01.2012
ES16.01.2012
IS05.02.2012
PT06.02.2012
IE28.04.2012
CH30.04.2012
LI30.04.2012
MC30.04.2012
Former [2012/28]BE05.10.2011
CY05.10.2011
LT05.10.2011
LV05.10.2011
NL05.10.2011
SE05.10.2011
SI05.10.2011
GR06.01.2012
IS05.02.2012
PT06.02.2012
Former [2012/24]BE05.10.2011
LT05.10.2011
LV05.10.2011
NL05.10.2011
SE05.10.2011
SI05.10.2011
GR06.01.2012
IS05.02.2012
PT06.02.2012
Former [2012/23]BE05.10.2011
LT05.10.2011
NL05.10.2011
SI05.10.2011
GR06.01.2012
IS05.02.2012
PT06.02.2012
Former [2012/21]BE05.10.2011
LT05.10.2011
SI05.10.2011
IS05.02.2012
Former [2012/20]LT05.10.2011
SI05.10.2011
Former [2012/11]SI05.10.2011
Documents cited:Search[X]EP1491205  (JURIDICAL FOUNDATION [JP]) [X] 1-15 * the whole document * * page 8; example 3 * * figures 1-3 *;
 [DX]  - CICHON J V JR ET AL, "The effect of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model.", THE LARYNGOSCOPE FEB 1995, (199502), vol. 105, no. 2, ISSN 0023-852X, pages 144 - 148, XP008104222 [DX] 1-15 * the whole document * * page 144 - page 145 * * figures 1,2 *

DOI:   http://dx.doi.org/10.1288/00005537-199502000-00006
 [X]  - DODD S L ET AL, "A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function", EUROPEAN JOURNAL OF NEUROLOGY, (199803), vol. 5, no. 2, ISSN 1351-5101, pages 181 - 186, XP002520878 [X] 1-15 * the whole document * * page 182 *

DOI:   http://dx.doi.org/10.1046/j.1468-1331.1998.520181.x
 [A]  - KOPMAN AARON F ET AL, "An alternate method for estimating the dose-response relationships of neuromuscular blocking drugs", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (200005), Database accession no. PREV200000243742, XP002520879 [A] 1-15 * abstract *
    [ ] - ANESTHESIA AND ANALGESIA, (200005), vol. 90, no. 5, ISSN 0003-2999, pages 1191 - 1197
Examination   - KIM HYEON SOOK ET AL, "Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis", DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, (2003), vol. 45, no. 3, pages 200 - 206
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.